The economic burden ofClostridioides difficileinfection in patients with hematological malignancies in the United States: A case-control study
Autor: | Lola Duhalde, Sebastian M. Wingen-Heimann, Lise Lurienne, Pierre-Alain Bandinelli, Lucien Guillou, Renaud Buffet |
---|---|
Rok vydání: | 2020 |
Předmět: |
Microbiology (medical)
medicine.medical_specialty genetic structures Epidemiology business.industry Case-control study MEDLINE Cancer Myeloid leukemia 030501 epidemiology medicine.disease Lymphoma 03 medical and health sciences 0302 clinical medicine Infectious Diseases Internal medicine medicine Health insurance In patient 030212 general & internal medicine 0305 other medical science business Clostridioides |
Zdroj: | Infection Control & Hospital Epidemiology. 41:813-819 |
ISSN: | 1559-6834 0899-823X |
DOI: | 10.1017/ice.2020.153 |
Popis: | Objective:The primary study aim was to describe all direct healthcare costs associated withClostridioides difficileinfection (CDI), both in and out of the hospital, in patients with hematologic malignancies in the United States.Design:A retrospective analysis was conducted utilizing data from US databases of Truven Health Analytics.Patients:We analyzed health insurance claims between January 2014 and December 2017 of patients diagnosed with hematological cancer: acute myeloid leukemia (AML), acute lymphoblastic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma (NHL).Methods:Patients with CDI after cancer diagnosis (CDI+, cases) were matched with patients without CDI reported (CDI−, controls). Matched cases and controls were compared to identify the CDI-associated costs in the 90 days following the onset of CDI.Results:We matched 622 CDI+ patients with 11,111 CDI− patients. NHL (41.7%) and AML (30.9%) were the predominant underlying diseases in the CDI+ groups. During study period, the average time in-hospital of CDI+ patients was 23.1 days longer than for CDI− patients (P< 2×10−16). Overall, CDI onset increased costs of care by an average of US$57,159 per patient (P= 6×10−12), mainly driven by hospital costs.Conclusions:This study confirms the significant economic burden associated with CDI in the United States, especially in patients with hematological malignancies. These findings highlight the need for prevention of CDI in this specific patient population. |
Databáze: | OpenAIRE |
Externí odkaz: |